Skip to main content

Decipher Biosciences, Inc. (DECI)

Decipher Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)33.26M
Net Income (ttm)-5.83M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About DECI

Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers. Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis,...

IndustryMedical Devices
IPO DatePending
CEOTina S. Nova, Ph.D.
Employees95
Stock ExchangeNASDAQ
Ticker SymbolDECI
Full Company Profile

Financial Performance

In 2019, DECI's revenue was $16.52 million, an increase of 36.89% compared to the previous year's $12.07 million. Losses were -$18.45 million, -38.37% less than in 2018.

Financial Statements

News

Genomics testing provider Decipher Biosciences files for a $100 million IPO

Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

8 months ago - NASDAQ

Decipher Biosciences IPO Registration Document (S-1)

Decipher Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC